Pulmatrix, Inc. (PULM) News

Pulmatrix, Inc. (PULM): $3.91

0.33 (+9.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PULM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 407

in industry

Filter PULM News Items

PULM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PULM News From Around the Web

Below are the latest news stories about PULMATRIX INC that investors may wish to consider to help them evaluate PULM as an investment opportunity.

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2022 and provided a corporate update related to its development programs.

Yahoo | August 8, 2022

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing of the first five subjects in a Phase 1 trial evaluating PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.

Yahoo | July 12, 2022

H.C. Wainwright Thinks Pulmatrix’s Stock is Going to Recover

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Pulmatrix (PULM – Research Report) today and set a price target of $10.00. The company's shares closed last Friday at $5.12, close to its 52-week low of $4.83. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -22.5% and a 22.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Pulmatrix has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

Catie Powers on TipRanks | May 16, 2022

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2022 and provided a corporate update.

Yahoo | May 12, 2022

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2021 and provided a corporate update.

Yahoo | March 29, 2022

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced positive top-line results of its recently completed Phase 1b clinical study of PUR1800, a narrow-spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE™ for evaluation in patients with stable Chronic Obstructive Pulmonary Disease (COPD). P

Yahoo | March 21, 2022

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC ("Nasdaq") stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Yahoo | March 17, 2022

PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?

Woah! It looks like Pulmatrix (NASDAQ:PULM) stock is up a gravity-defying 1,800% today as the tiny pharmaceutical company executes a 1-for-20 reverse stock split. Source: Shutterstock So what do you need to know? On Friday, Feb. 25, Pulmatrix stock closed at just 32 cents a share. Today, the stock is changing hands at $6.17. The vault higher is really the Lexington, Massachusetts-based company undertaking a reverse stock split.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What H

Yahoo | March 1, 2022

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced the hiring of Dr. Margaret Wasilewski as the Company's Chief Medical Officer effective March 1st, 2022.

Yahoo | March 1, 2022

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced a 1-for-20 reverse split of its common stock, to be effective as of 4:05 p.m. Eastern Time on February 28, 2022. The Company's common stock is expected to trade on the Nasdaq Capital Market on a split-adjusted-basis when the market opens on Mar

Yahoo | February 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5271 seconds.